Angela Celetti

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 9

Top Topics

Tyrosine Kinase

Advanced Non Small Cell Lung Cancer

Top Venues

Journal of experimental & clinical cancer research : CR

Exploration of targeted anti-tumor therapy

Molecular cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Daniela Criscuolo, Francesco Morra, Angela Celetti
A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options. Exploration of targeted anti-tumor therapy 3 (5) (2022)
Francesco Morra, Francesco Merolla, Giovanna Damia, Francesca Ricci, Silvia Varricchio, Gennaro Ilardi, Laura Arenare, Daniela Califano, Virginia Napolitano, Robert Fruscio, Rosa Marina Melillo, Luca Palazzo, Angela Celetti
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma. Journal of experimental & clinical cancer research : CR 41 (1) (2022)
Virginia Napolitano, Daniela Russo, Francesco Morra, Francesco Merolla, Silvia Varricchio, Gennaro Ilardi, Rosa Maria Di Crescenzo, Francesco Martino, Massimo Mascolo, Angela Celetti, Luca Tamagnone, Stefania Staibano
Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress. Cancers 13 (15) (2021)
Daniela Criscuolo, Francesco Morra, Riccardo Giannella, Roberta Visconti, Aniello Cerrato, Angela Celetti
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment. Journal of experimental & clinical cancer research : CR 38 (1) (2019)
Francesco Morra, Francesco Merolla, Ida Picardi, Daniela Russo, Gennaro Ilardi, Silvia Varricchio, Federica Liotti, Roberto Pacelli, Luca Palazzo, Massimo Mascolo, Angela Celetti, Stefania Staibano
CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC. Cancers 11 (10) (2019)
Aniello Cerrato, Francesco Morra, Imma Di Domenico, Angela Celetti
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells. Cancers 12 (1) (2019)
Francesco Morra, Francesco Merolla, Daniela Criscuolo, Luigi Insabato, Riccardo Giannella, Gennaro Ilardi, Aniello Cerrato, Roberta Visconti, Stefania Staibano, Angela Celetti
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer. Journal of experimental & clinical cancer research : CR 38 (1) (2019)
Aniello Cerrato, Roberta Visconti, Angela Celetti
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer. Molecular cancer 17 (1) (2018)
Aniello Cerrato, Francesco Merolla, Francesco Morra, Angela Celetti
CCDC6: the identity of a protein known to be partner in fusion. International journal of cancer 142 (7) (2017)